Addiction - Articles - Page 2 | CARLAT PUBLISHING

Research Update

Does Cannabis Legalization Increase the Risk of Driving-Related Injury?

July 1, 2024

Garrett Rossi, MD. Dr. Rossi has no financial relationships with companies related to this material.

Everyone knows that it is dangerous to drive while under the influence of alcohol—but what about cannabis? This study adds to a growing body of evidence that cannabis can be hazardous to safety on the road, a particularly important message to get out to patients as legalization becomes increasingly common.

Clinical Update

Drug Testing and the Legal System

July 1, 2024

Paul A. Bryant, MD

Paul A. Bryant, MD, Assistant Professor of Psychiatry; Stephanie Eng, MD, Fellow in Forensic Psychiatry; Melissa Lavoie, MD, Fellow in Forensic Psychiatry. Yale University, New Haven, CT.

Drs. Bryant, Eng, and Lavoie have no financial relationships with companies related to this material.

Urine drug screens are frequently ordered for patients receiving addiction treatment. However, the results of these everyday tests can have outsized consequences for patients involved in the legal system. Here, we provide an overview of how drug testing is used in the legal system and how you can be an advocate for your patient.

Expert Q&A

Pregnancy, Addiction, and the Law

July 1, 2024

Elisabeth Johnson, PhD, FNP-BC, CARN-AP, LCAS

Elisabeth Johnson, PhD, FNP-BC, CARN-AP, LCAS.

Division Director, UNC Horizons; Clinical Assistant Professor,UNC-Chapel Hill, Carrboro, NC.

Dr. Johnson has no financial relationships with companies related to this material.

Dr. Johnson tells us all about Child Protective Services and how they work with pregnant patients who use substances. In this interview, she reviews the role of medical and mental health providers in the care of pregnant patients with addictive disorders and their legal obligations. She also provides tips for discussing these sensitive matters with your patients.

Clinical Update

A Clinician’s Guide to Drug Courts

July 1, 2024

Stephen Wemakor, MD and Noah Capurso, MD

Stephen Wemakor, MD, Department of Psychiatry, Yale University, New Haven, CT; Noah Capurso, MD, MHS, Assistant Professor of Psychiatry, Yale University, & Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Wemakor and Capurso have no financial relationships with companies related to this material.

Many of your patients with substance use disorders will become involved with the legal system over the course of their work with you, and one of the most common avenues is through the drug
court system. Here, we provide the basics of how drug courts function and review how best to work with these courts when they request information.

CARLAT WEBINAR

Carlat Psychiatry News - Episode 2 - TMS for Teens

June 1, 2024

Chris Aiken, MD, Greg Malzberg, MD, and Kellie Newsome, PMHNP

0.25 CME Credits. Psychiatric news covered in this episode: TMS for Teens, Olanzapine Serum Levels, Old Medication Pairing Emerges for Novel Alcoholism Treatment, Old Medication Pairing Emerges for Novel Alcoholism Treatment, Promising Option For Transitioning Insomnia Medications, Lithium's Anti-Suicide Effects in Question, Role of Omega-3 Supplements in Psychosis Risk Reduction, Caffeine and Anxiety: A Concerning Connection for Coffee Lovers.

Stimulant Update with Dr. Brian Hurley

April 15, 2024

Noah Capurso, MD and Brian Hurley, MD, MBA, FAPA, DFASAM

In today's episode, Dr. Brian Hurley provides expert insights into the current state of stimulant use disorder, its implications across different regions, and available treatment options.

CARLAT WEBINAR

Carlat Psychiatry News - Episode 1 - MDMA-Assisted Therapy for PTSD

April 1, 2024

Chris Aiken, MD, Greg Malzberg, MD, and Kellie Newsome, PMHNP

0.25 CME Credits. Psychiatric news covered in this episode: FDA Grants Priority Review for MDMA Therapy, Benzodiazepine Withdrawal Perils, Lithium: Good for Bones?, Iloperidone Added to Anti-Psychotics with Mania Efficacy, Transdiagnostic Sleep and Circadian Treatment, A Door Closes for Clozapine-Resistant Schizophrenia, Therapy for Multi-Trauma PTSD.

Research Update

Buprenorphine versus Methadone for Prescription Opioid Use Disorder

April 1, 2024

Richard Moldawsky, MD

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

Methadone treatment for OUD typically comes with a high level of supervision whereas buprenorphine is often flexibly dosed and taken at home. Here researchers wanted to know how patients of a closely supervised methadone clinic compared with those taking buprenorphine prescribed in an office setting. The findings might surprise you.

Clinical Update

Three Buprenorphine Dosing Strategies When Transitioning From Other Opioids

April 1, 2024

Monthe Kofos, DO and Noah Capurso, MD

Monthe Kofos, DO. Addiction Psychiatry Fellow, Yale University, New Haven, CT.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Kofos and Dr. Capurso have no financial relationships with companies related to this material.

The process of starting a patient on buprenorphine, called an induction, can be a bit tricky and puts a patient at risk of a precipitated opioid withdrawal. In this article, we discuss the three most common buprenorphine induction approaches, review the pros and cons of each, and include straightforward guidance that will help you perform a successful buprenorphine induction for your patients.

Expert Q&A

Psychedelics and Addiction

April 1, 2024

Snehal Bhatt, MD

Snehal Bhatt, MD.

Chief, Addiction Psychiatry; Professor, Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM.

Dr. Bhatt has no financial relationships with companies related to this material.

Dr. Bhatt outlines the latest developments in therapeutic uses of psychedelic medications. He highlights the great opportunities as well as the potential drawbacks. He details some of his own work in the use of psilocybin for the treatment of alcohol use disorder and advises clinicians how to discuss psychedelics with their patients.